Last updated on July 9, 2026 · Originally published June 24, 2026
Walk into almost any cannabis dispensary and ask what helps with sleep. The answer, almost universally, is THC. It’s sedating, it knocks you out, it’s been the go-to for cannabis users with insomnia for decades. The science, though, is telling a more complicated story — and the gap between what dispensaries recommend and what researchers are actually finding is worth understanding.
A systematic review and meta-analysis published in June 2026 in the Journal of the American Association of Nurse Practitioners, led by Dr. Andrea Efre at the University of South Florida College of Nursing, looked at the available evidence on medical cannabis for insomnia. The finding was notable: emerging evidence suggests CBD and CBN may improve sleep quality with fewer adverse effects than THC — though the researchers were careful to note that larger trials are still needed before drawing firm conclusions. THC-containing formulations, across the studies reviewed, produced mixed results and were associated with higher rates of adverse effects.
That’s a meaningful challenge to the conventional dispensary wisdom, even if it’s not yet a closed case.
Why THC Got the Sleep Reputation
THC’s reputation as a sleep aid isn’t entirely unfounded. It does reduce the time it takes to fall asleep — a property called sleep latency – and many users report feeling sedated after use. For anyone who has lain awake staring at the ceiling for hours, that initial sedation is appealing enough to become habit. For some patient populations – those with chronic pain, chemotherapy-related symptoms, or PTSD nightmares – THC-containing formulations can be genuinely effective, and the right tool for the job.
The question is what happens during sleep for the broader population of users, not just at the onset of it. THC suppresses REM sleep — the sleep stage associated with dreaming, emotional processing, and memory consolidation. A 2026 pilot randomized controlled trial from the Woolcock Institute of Medical Research at Macquarie University, published in the Journal of Sleep Research, used high-density EEG to measure sleep architecture in 20 insomnia patients who received a single oral dose of 10mg THC combined with 200mg CBD. The results were striking: REM sleep decreased by an average of 33.9 minutes, and total sleep time was reduced by nearly 25 minutes compared to placebo.
It’s worth noting the limitations here. This was a small pilot trial – 20 participants, a single dose, one night in a lab. It tells us something real about the acute physiology, but it can’t tell us how those effects play out over weeks or months of real-world use, or whether they’re consistent across different doses, formulations, and patient types.
The participants subjectively felt slightly sleepier after the cannabinoid treatment — but objectively, they slept less and spent significantly less time in REM. One recurring theme in cannabinoid sleep research is the mismatch between subjective and objective outcomes: participants often report sleeping better even when laboratory measurements show little improvement – or in some cases reduced REM sleep and total sleep time. Whether that REM reduction matters clinically is a genuinely open question.
Many widely prescribed medications, including certain antidepressants, also suppress REM sleep, and patients on those drugs often function well. The difference is that with prescription drugs, that trade-off is usually an acknowledged part of the clinical decision. Cannabis users reaching for a sleep gummy typically don’t know their REM is being blunted – or whether it matters for them personally.
What Happens When You Stop
One of the more well-established concerns around THC and sleep isn’t the effect during use – it’s what happens during cessation. Regular THC use suppresses REM sleep over time, and when use stops — even briefly – the brain overcorrects. REM rebounds sharply, which often means intense dreaming and disrupted sleep in the nights following cessation. This rebound effect is well-documented and helps explain why cannabis-dependent sleep can be difficult to step back from. The compound someone is using to sleep better can make it harder to sleep without it.
This pattern is much less pronounced with CBD or CBN, neither of which produces the same degree of CB1 receptor adaptation associated with THC’s withdrawal effects.
The Case for CBD and CBN — With Caveats
CBD (cannabidiol) works differently from THC at a fundamental pharmacological level. It doesn’t bind directly to the CB1 receptors that THC targets, and it doesn’t produce intoxication. Its sleep effects appear to be largely indirect — reducing anxiety, lowering physiological arousal, and addressing the underlying hyperarousal that characterizes insomnia for many people. For a condition often driven by a nervous system that won’t settle down, that mechanism makes intuitive sense.
The Efre review found that CBD doses between 50 and 300mg were associated with the most consistent sleep improvements. Lower doses – particularly below 50mg – generally showed little benefit unless combined with CBN.
CBN (cannabinol) is the lesser-known of the two and is attracting growing research interest. It forms naturally as THC ages and oxidizes, which is why older cannabis has long had a folk reputation for being more sedating. CBN binds to CB1 receptors with much lower affinity than THC, producing mild effects without significant intoxication. The Efre review found CBN doses between 20 and 100mg to be associated with sleep improvements, and combinations of CBD and CBN appeared to perform better than either alone.
The honest caveat here is that CBN research remains relatively limited compared to either THC or CBD. A double-blind, placebo-controlled trial published in Experimental and Clinical Psychopharmacology found that CBN combined with CBD improved sleep maintenance without the adverse effects associated with THC – but the field is still in early stages. The commercial market has already moved well ahead of the evidence, with CBN-branded sleep products proliferating faster than the clinical data can keep up. Promising is the right word; definitive is not.
The Market Hasn’t Caught Up
Despite this emerging evidence, the cannabis sleep market remains heavily THC-focused. Products marketed for sleep – tinctures, gummies, capsules – still predominantly lead with THC content. CBN products exist but occupy a smaller shelf presence, and consumer awareness of the distinction between cannabinoids for sleep remains low.
Part of this is structural. THC is the compound the cannabis industry has always organized around. Consumers ask for it by name, and dispensary staff are trained to recommend it. CBN and CBD are more associated with the hemp market than the dispensary channel, which creates its own complications for how they’re positioned and explained.
But for medical patients, older adults, and people using cannabis specifically to address sleep without intoxication, the difference between these compounds matters – and the evidence increasingly suggests it’s worth discussing.
Where the Science Actually Sits
The picture emerging from the current research is not that THC is bad for sleep across the board – it’s that it works differently than most users assume, and for different populations than those it’s most commonly marketed to. For someone with chronic pain or PTSD-related nightmares, THC’s sedating and REM-suppressing properties may be exactly what’s needed. For someone with anxiety-driven insomnia who simply wants to sleep better and wake up clear-headed, the evidence now leans toward CBD, CBN, or combinations of the two.
Larger, longer, better-powered trials are still needed to establish optimal doses, formulations, and patient profiles. The Efre review and the Suraev EEG study are meaningful contributions to a literature that is growing but still incomplete. What they collectively suggest is that the conversation in dispensaries – and in clinical settings — needs to get more specific about which cannabinoid, for which patient, and for which type of sleep problem. A single answer was probably always too simple for a condition as varied as insomnia.
Sources: Efre A et al., “Medical Cannabis for Insomnia: A Systematic Review and Meta-Analysis,” Journal of the American Association of Nurse Practitioners, June 2026. Suraev A et al., “Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia,” Journal of Sleep Research, 2026. Bonn-Miller MO et al., “A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on Sleep Quality,” Experimental and Clinical Psychopharmacology, 2024.
